Venezuela (Bolivarian Republic of) Tuberculosis profile

Population 2017 32 million

***
Rate (Rate per 100 000 population per year)
Estimates of TB burden*, 2017 Number (thousands) (per 100 000 population) 4
Mortality (excludes HIV+TB) 0.8 (0.75–0.84) 2.5 (2.3–2.6) 3
Mortality (HIV+TB only) 0.26 (0.19–0.35) 0.82 (0.59–1.1)
2
Incidence (includes HIV+TB) 13 (10–17) 42 (32–53)
Incidence (HIV+TB only) 1.2 (0.89–1.5) 3.7 (2.8–4.8) 1
Incidence (MDR/RR-TB)** 0.42 (0.16–0.79) 1.3 (0.5–2.5) 0
2000 2004 2008 2012 2016
Estimated TB incidence by age and sex (thousands)*, 2017
0-14 years > 14 years Total Mortality (excludes HIV+TB)
Females 0.84 (0.52–1.2) 3.8 (2.3–5.2) 4.6 (3.1–6.2)
Males 0.93 (0.58–1.3) 7.8 (4.8–11) 8.7 (5.8–12) (Rate per 100 000 population per year)
Total 1.8 (1.3–2.3) 12 (8.3–15) 13 (10–17) 60

40
TB case notifications, 2017
Total cases notified 10 952
20
Total new and relapse 10 647
- % tested with rapid diagnostics at time of diagnosis 0
- % with known HIV status 60% 2000 2004 2008 2012 2016
- % pulmonary 89%
- % bacteriologically confirmed among pulmonary 76% Incidence
Notified (new and relapse)
Universal health coverage and social protection Incidence (HIV+TB only)
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs Notified cases by age group and sex, 2017
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.08 (0.06–0.1) 65+
55-64
TB/HIV care in new and relapse TB patients, 2017 Number (%)
45-54
Patients with known HIV-status who are HIV-positive 528 8%
35-44
- on antiretroviral therapy 300 57%
25-34
Previously treated Total 15-24
Drug-resistant TB care, 2017 New cases cases number*** 05-14
Estimated MDR/RR-TB cases among notified 300 0-4
pulmonary TB cases (130–470) 1000 0 1000 2000 3000
Estimated % of TB cases with MDR/RR-TB 2.3% (0.79–4.5) 13% (8.4–18)
% notified tested for rifampicin resistance 5% 48% 843 __ Females __ Males _ Incidence
MDR/RR-TB cases tested for resistance to second-line drugs 67
Laboratory-confirmed cases MDR/RR-TB: 79, XDR-TB: 2 Treatment success rate (%)
Patients started on treatment **** MDR/RR-TB: 72, XDR-TB: 2 100
80
Treatment success rate and cohort size Success Cohort 60
New and relapse cases registered in 2016 82% 8 197 40
Previously treated cases, excluding relapse, registered in 2016 62% 345
20
HIV-positive TB cases registered in 2016 81% 585 0
MDR/RR-TB cases started on second-line treatment in 2015 71% 31 2000 2002 2004 2006 2008 2010 2012 2014 2016
XDR-TB cases started on second-line treatment in 2015 100% 1
New and relapse
TB preventive treatment, 2017 Retreatment, excluding relapse
% of HIV-positive people (newly enrolled in care) on preventive treatment HIV-positive MDR/RR-TB XDR-TB
% of children (aged < 5) household contacts of bacteriologically-confirmed 100% (75–100)
TB cases on preventive treatment Total budget (US$ millions)
3
TB financing, 2018
National TB budget (US$ millions) 2.9 2
Funding source: 14% domestic, 0% international, 86% unfunded
1
* Ranges represent uncertainty intervals
0
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history 2014 2015 2016 2017 2018
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
__ Unfunded
__ Funded internationally
__ Funded domestically

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-04-14 Data: www.who.int/tb/data